3781Annual report 2021: WHO Asia-Pacific Centre for Environment and Health in the Western Pacific RegionTechnical Documents · 15 марта 2022 г.
3782Annexes to the interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: grading of evidence: evidence to recommendations tables, first issued 3 November 2021, last updated 15 March 2022Technical Documents · 15 марта 2022 г.
3783Behavioural and Cultural Insights and the fight against Antimicrobial ResistanceTechnical Documents · 15 марта 2022 г.
3784Поведенческие и культурные инсайты и борьба с устойчивостью к противомикробным препаратамTechnical Documents · 15 марта 2022 г.
3785COVID-19 weekly epidemiological update, edition 83, 15 March 2022Technical Documents · 15 марта 2022 г.
3786Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm: interim guidance, first issued 7 May 2021, updated 28 October 2021, updated 15 March 2022Technical Documents · 15 марта 2022 г.
3787Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac: interim guidance, first issued 24 May 2021, updated 21 October 2021, updated 15 March 2022Technical Documents · 15 марта 2022 г.
3789Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™): grading of evidence: evidence to recommendations tables, first issued 10 February 2021, updated 21 April 2021, updated 30 July 2021, last updated 15 March 2022Technical Documents · 15 марта 2022 г.
3790Борьба с устойчивостью к противомикробным препаратам требует внимания к гендерным вопросамTechnical Documents · 15 марта 2022 г.
3791Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence: evidence to recommendation tables, first issued 24 May 2021, updated 21 October 2021, last updated 15 March 2022Technical Documents · 15 марта 2022 г.
3792Tuberculosis and the fight against Antimicrobial ResistanceTechnical Documents · 15 марта 2022 г.
3793Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™): interim guidance, first issued 10 February 2021, updated 21 April 2021, updated 30 July 2021, latest update 15 March 2022Technical Documents · 15 марта 2022 г.
3795Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19: interim guidance, first issued 3 November 2021, updated 15 March 2022Technical Documents · 15 марта 2022 г.
3796Emergency in Ukraine: external situation report #1, published 5 March 2022: reporting period: 24 February– 3 March 2022Technical Documents · 14 марта 2022 г.
379721st Meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE): virtual meeting, hosted in Copenhagen, Denmark 16–18 November 2021Technical Documents · 14 марта 2022 г.
3798Virtual cGMP training marathon for vaccine manufacturing: questions and answers, 05 October – 11 November 2021Technical Documents · 14 марта 2022 г.
3799Strengthening COVID-19 vaccine demand and uptake in refugees and migrants: an operational guide to support all those responsible for planning and implementing the rollout of COVID-19 vaccine to refugees and migrants at national and local levels, 14 March 2022Technical Documents · 14 марта 2022 г.
3800Safety monitoring of molnupiravir for treatment of mild to moderate COVID-19 infection in low and middle-income countries using cohort event monitoring: a WHO study, 11 March 2022Technical Documents · 11 марта 2022 г.